Back
Results - Announcements
Medicamen Biotech Ltd consolidated sales down 21.02% on year in Q2FY2026, net profit tumbled by 58.43%
14-Aug-2026, 07:35
Medicamen Biotech Ltd share price ticked higher by 2.53% to Rs 242.75. The Company's net profit tanked by 58.43% to Rs 1.85 crore, while revenue from operations plunged by 21.02% to Rs 47.9 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.63%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Medicamen Biotech Ltd has improved by 2.99% and 13.35% in the same period respectively. Profit before tax (PBT) of Medicamen Biotech Ltd stood at Rs 2.57 crore in Q2 FY26, surging by 20.66% year-on-year, and tumbling by 49.21% quarter-on-quarter. EBITDA came in at Rs 3 crore, plunging by 16.18% YoY and slipping 6.22% sequentially. Total expenses saw a steep drop of 20.34% to Rs 45.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 22.61 crore, contracting by 13.34% YoY, while employee benefits expense was at Rs 9.31 crore, slipping by 0.96% YoY. For the TTM ended FY26, revenue from operations eased 9.35% to Rs 162.55 crore, while net profit witnessed a sharp fall of 30.87% to Rs 6.56 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1889% to Rs 7.62 crore, and PBT collapsed by 24.46% to Rs 9.88 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 7.19 crore in FY26, as against Rs 0.37 crore in FY25. Medicamen Biotech Ltd nosedived by 29.78% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.05% during the same period.
Medicamen Biotech Ltd share price ticked higher by 2.53% to Rs 242.75. The Company's net profit tanked by 58.43% to Rs 1.85 crore, while revenue from operations plunged by 21.02% to Rs 47.9 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.63%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Medicamen Biotech Ltd has improved by 2.99% and 13.35% in the same period respectively. Profit before tax (PBT) of Medicamen Biotech Ltd stood at Rs 2.57 crore in Q2 FY26, surging by 20.66% year-on-year, and tumbling by 49.21% quarter-on-quarter. EBITDA came in at Rs 3 crore, plunging by 16.18% YoY and slipping 6.22% sequentially. Total expenses saw a steep drop of 20.34% to Rs 45.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 22.61 crore, contracting by 13.34% YoY, while employee benefits expense was at Rs 9.31 crore, slipping by 0.96% YoY. For the TTM ended FY26, revenue from operations eased 9.35% to Rs 162.55 crore, while net profit witnessed a sharp fall of 30.87% to Rs 6.56 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1889% to Rs 7.62 crore, and PBT collapsed by 24.46% to Rs 9.88 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 7.19 crore in FY26, as against Rs 0.37 crore in FY25. Medicamen Biotech Ltd nosedived by 29.78% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.05% during the same period.